Market key trends:
One of the key trends witnessed in the market currently is the rise in use of theragnostic radiopharmaceuticals. Theragnostics combines therapeutics and diagnostics into a single drug which allows personalizing treatments for patients. These radiopharmaceuticals help improve clinical outcomes by allowing providers to accurately diagnose the disease and simultaneously treat it with personalized radiation therapy. Research is ongoing to develop advanced theragnostic agents with improved tumor targeting ability and reduced side effects. Development of such innovative radiopharmaceuticals will strengthen personalized cancer care in the coming years.

Key Takeaways
Global Oncology Radiopharmaceuticals Market Demand is expected to witness high growth, exhibiting a CAGR of 45% over the forecast period, due to increasing incidences of cancer worldwide.

Regional analysis - North America dominated the market in 2023 and is expected to continue its dominance over the forecast period. This is attributed to growing adoption of nuclear medicine procedures and availability of advanced diagnostic technologies in the region. Asia Pacific is expected to be the fastest growing region during the forecast period owing to large patient pool and rising healthcare expenditure in the region.

Key players - Key players operating in the oncology radiopharmaceuticals market are Siemens Healthcare GmbH, Novartis AG, Curium, GE Healthcare, Lantheus Medical Imaging, Inc., International Isotopes, Inc., Nordion, Eckert & Zieger, Acrotech Biopharma, Blue Earth Diagnostics, Zionexa, Bayer AG, Jubilant Pharma Limited, and Cardinal Health.

Get More Insights on this Topic-